Kidney Cancer

P1, N=3, Recruiting, Peking University Cancer Hospital & Institute

P1, N=11, Recruiting, Brian Henick, MD | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: May 2026 --> May 2027

These patients had a higher frequency of bilateral WT and a higher rate of abnormalities compared to patients without aberrations (56% vs. 25%, p = 0.002; and 86% vs. 25%, p < 0.0001, respectively). The detection of WT hereditary predisposing factors is crucial for treatment strategies and long-term patient surveillance.

Girentuximab PET-CT is a highly accurate, CAIX-targeted molecular imaging technique with the potential to transform the diagnostic pathway of ccRCC. While current evidence supports its use in selected localized settings, broader clinical adoption will require prospective validation of its impact on patient outcomes and management strategies.

P=N/A, N=120, Active, not recruiting, Istituto Oncologico Veneto IRCCS | Recruiting --> Active, not recruiting

P=N/A, N=3, Active, not recruiting, IRCCS San Raffaele | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> May 2026 | Trial primary completion date: Oct 2025 --> May 2026

Intense radiotracer uptake was observed not only in the primary renal tumor, but also in a focal lesion in the left thyroid lobe. This case highlights the potential utility of CAIX-targeted PET/CT imaging for visualizing primary and metastatic ccRCC, including uncommon metastatic sites.

The non-cystic MED15::TFE3 RCCs also have unique fusion transcripts that are different from those seen in the conventional MED15::TFE3 RCCs. The phenotypic variation of MED15::TFE3 RCCs may be due to the property of the fusion transcripts, although additional studies are required to validate this finding.

Moreover, the imaging findings changed clinical management in 58.7% of patients. &lsqb;18F]RCCB6 PET/CT is a highly sensitive imaging modality for diagnosing ccRCC metastases and informing clinical decision-making.

Intraoperative frozen section analysis aids in determining the surgical approach (nephron-sparing vs. radical resection) for patients with lesions that are difficult to distinguish as benign or malignant prior to surgery. Pathological hallmarks and supporting IHC (PAX-8, ER/PR) remain the diagnostic gold standard.

The presence of a germline WT1 variant increases the risk of intralobar nephrogenic rests, bilateral WT, typically with onset at an earlier age. Because of this elevated and distinct risk profile management differs from that of sporadic WT.

These results indicated that vaccine-induced VISTA blockade effectively amplifies DC-mediated CD8+ T-cell immunity and synergistically enhances tumor vaccine efficacy. Targeting VISTA represents a promising immunotherapeutic strategy for improving vaccine-based treatments in renal carcinoma.